Estimating the burden of scleroderma disease in Spain

Journal of Rheumatology

Volumn 34, Issue 11, 2007, Pages 2236-2242

  Villaverde Hueso, Ana ^a   Sánchez Valle, Elena ^a   Álvarez, Elena ^b   Morant, Consuelo ^c   Carreira, Patricia E ^d   Martín Arribas, María Concepción ^a   Gènova, Ricard ^c   Ramírez González, Alejandro ^a   Posada De La Paz, Manuel ^a,e  

^a Ministry of Science and Innovation   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c Grupo de Intervencion en Drogas de la Sociedad Espanola de Medicina Familiar Y Comunitaria   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Burden of disease; Disability; Epidemiology; Rare diseases; Scleroderma; Systemic sclerosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CALCULATION; CHILD; DEVELOPED COUNTRY; DISABILITY; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; SCLERODERMA; SPAIN; SYSTEMIC SCLEROSIS; WORLD HEALTH ORGANIZATION;

EID: 35948951184     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. US Food and Drug Administration. The Orphan Drug Act. Washington, DC: US Food and Drug Administration; 1983. Available from: www.fda.gov/orphan/oda.htm (accessed August 3, 2007).
2. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 2002;81:139-53.
3. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
4. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998;37:750-5.
5. Simeon CP, Armadans L, Fonollosa V, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology Oxford 2003;42:71-5.
6. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
7. Nishioka K, Katayama I, Kondo H, et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis. Scleroderma Research Committee Japan. J Dermatol 1996;23:677-82.
8. Posada de la Paz M, Martínez López de Letona J, Masa Vázquez C, et al. Esclerosis sistémica progresiva. Un problema diagnóstico. Rev Clin Esp 1983;170:237-41.
9. Medsger TA Jr. Classification of systemic sclerosis. In: Jayson MIV, Black CM, editors. Systemic sclerosis: scleroderma. London: John Wiley; 1988:1-6.
10. Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13:911-6.
11. Chandran G, Smith M, Ahern MJ, et al. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. Aust NZ J Med 1995;25:688-94.
12. Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005;34:714-20.
13. UK Scleroderma Study group. How can treatment of systemic sclerosis be improved? BMJ 1998;317:294-5.
14. Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 2001;23:231-47.
15. Valesini G, Litta A, Bonavita MS, et al. Geographical clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol 1993;11:41-7.
16. Roberts-Thomson PJ, Jones M, Hakendorf P, et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern Med J 2001;31:220-9.
17. Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum Dis Clin North Am 2003;29:211-37.
18. Arnesen T, Nord E. The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ 1999;319:1423-5.
19. Victorian Burden of Disease Study (2005). Mortality and Morbidity in 2001. Public Health Group. Melbourne: Victorian Government Department of Human Services; 2005. Available at: http://www.health.vic.gov.au/healthstatus/bod/ bod_vic.htm (accessed August 3, 2007).
20. Murray CJL, Salomon JA, Mathers C. A critical examination of summary measures of population health. Bull World Health Organ 2000;78:981-94.
21. Schopper D, Pereira J, Torres A, et al. Estimating the burden of disease in one Swiss canton: what do disability adjusted life years (DALY) tell us? Int J Epidemiol 2000;29:871-7.
22. Skull SA, Butler JRG, Robinson P, Carnie J. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation. Int J Epidemiol 2001;30:571-8.
23. Strong K, Mathers C, Epping-Jordan J, Beaglehole R. Preventing chronic disease: a priority for global health. Int J Epidemiol 2006;35:492-4.
24. Murray CJL, López AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Global Burden of Disease and Injury. Harvard School of Public Health on behalf of WHO. Cambridge, MA: Harvard University Press; 1996.
25. Cifras de Población. Revisión del Padrón Municipal 2001. Madrid: Instituto Nacional de Estadística (INE). Available from: www.ine.es/inebase/index.html (accessed August 3, 2007).
26. Instituto Nacional de Estadística. Fichero de microdatos individuales de defunciones con causa de muerte. Año 2001. Madrid: Instituto Nacional de Estadistica; 2001.
27. World Health Organization (WHO). International statistical classification of diseases and related health problems, 10th revision, ICD-10, vols. 1-3. Geneva: World Health Organization; 1992-1994.
28. Coale A, Guo G. Revised regional model life tables at very low levels of mortality. Popul Index 1989;55:613-43.
29. Silman A, Jannini S, Symmons D, et al. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988;27:286-90.
30. Mayes MD. The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis. Curr Rheumatol Rep 2000;2:512-6.
31. Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology Oxford 2004;43:596-602.
32. Englert H, Small-McMahon J, Davis K, et al. Systemic sclerosis prevalence and mortality in Sydney 1974-88. Aust NZ J Med 1999;29:42-50.
33. Le Guern V, Mahr A, Mouthon L, et al. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology Oxford 2004;43:1129-37.
34. Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003;29:255-73.
35. DisMod II. Software developed by J. Barendregt, Department of Public Health, Erasmus University, Rotterdam. In collaboration with the WHO. Available from: www.hsph.harvard.edu/Organizations/bdu/DisMod.html (accessed August 3, 2007).
36. Stouthard MEA, Essink-Bot ML, Bonsel GJ, et al. Disability weights for diseases in The Netherlands. Rotterdam: Department of Public Health, Erasmus University; 1997.
37. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006;21:402-8. doi:10.1093/heapol/czl018.
38. Khanna D, Ahmed M, Furst DE, et al. Health values of patients with systemic sclerosis. Arthritis Rheum 2007;57:86-93.
39. GesMor: Software developed by the International Health Department, Carlos III Institute of Public Health (Instituto de Salud Carlos III). Supported by the Mexican Health Foundation (FUNSALUD) and the Interamerican Bank for Development. Available from: http://www.funsalud.org.mx/red-jlb/gesmor.htm (accessed August 3, 2007).
40. Alvarez E, Génova R, Morant C, Freire JM. Estimación de la carga de enfermedad de España en el año 2000. Gac Sanit 2004; 18 Supl 3:36.
41. Genova R, Alvarez E, Morant C. Carga de enfermedad y tendencias de morbilidad de la población española. In: Puyol R y Abellán A (coord). Envejecimiento y dependencia. Una mirada al panorama futuro de la población española. Madrid: Mundial Assistance; 2006:91-108.
42. Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997;27:73-84.
43. Smyth AE, MacGregor AJ, Mukerjee D, et al. A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology Oxford 2003;42:732-8.
44. Belotti Masserini A, Zeni S, Cossutta R, Soldi A, Fantini F. Analisi dei costi nella sclerosi sistemica. Studio retrospettivo in una casistica di 106 pazienti. [Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients]. Reumatismo 2003;55:245-55.
45. Kircher T, Nelson J, Burdo H. The autopsy as a measure of accuracy of the death certificate. N Engl J Med 1985;313:1263-9.
46. Silman AJ. Mortality from scleroderma in England and Wales 1968-1985. Ann Rheum Dis 1991;50:95-6.
47. Mayes MD. Epidemiology of systemic sclerosis and related diseases. Curr Opin Rheumatol 1997;9:557-61.
48. Mérida Fernández SM, Margolles Martins M. Enfermedades raras: La esclerosis sistémica (esclerodermia) en Asturias, 1996-2003. Gac Sanit 2005;19 Suppl 1:72.
49. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 1996;22:751-64.
50. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4:27-31.
51. Danieli E, Airo P, Bettoni L, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005;24:48-54.
52. Matsuura E, Ohta A, Kanegae F, et al. Frequency and analysis of factors closely associated with the development of depressive symptoms in patients with scleroderma. J Rheumatol 2003;30:1782-7.
53. Cubo E, Álvarez E, Morant C, et al. Burden of disease related to Parkinson's disease in Spain in the year 2000. Mov Disord 2005;20:1481-7.
54. Pereira Candel J, Cañón Campos J, Álvarez Martín E, et al. La medida de la magnitud de los problemas de salud en el ámbito internacional: los estudios de carga de enfermedad. Rev Admin Sanitaria 2001;19:441-66.
55. World Health Organization. Global burden of disease estimates. GBD 2001 estimates by sub-region. Available at: http://www.who.int/healthinfo/ bodestimates/en/index.html (accessed August 3, 2007).
56. Wurthwein R, Gbangou A, Sauerborn R, Schmidt CM. Measuring the local burden of disease. A study of years of life lost in sub-Saharan Africa. Int J Epidemiol 2001;30:501-8.
57. Ebrahim S, Lau E. Commentary: Sick populations and sick individuals. Int J Epidemiol 2001;30:433-4.